164 related articles for article (PubMed ID: 15478042)
41. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial).
Grundy SM; Vega GL; Yuan Z; Battisti WP; Brady WE; Palmisano J
Am J Cardiol; 2005 Feb; 95(4):462-8. PubMed ID: 15695129
[TBL] [Abstract][Full Text] [Related]
42. Status of "familial combined hyperlipidemia".
Brunzell JD; Motulsky AG
Prog Clin Biol Res; 1984; 147():403-5. PubMed ID: 6739492
[No Abstract] [Full Text] [Related]
43. Effect of aging and obesity on the expression of dyslipidaemia in children from families with familial combined hyperlipidaemia.
ter Avest E; Sniderman AD; Bredie SJ; Wiegman A; Stalenhoef AF; de Graaf J
Clin Sci (Lond); 2007 Jan; 112(2):131-9. PubMed ID: 17054424
[TBL] [Abstract][Full Text] [Related]
44. Molecular mechanisms, prevalence, and molecular methods for familial combined hyperlipidemia disease: A review.
Taghizadeh E; Mardani R; Rostami D; Taghizadeh H; Bazireh H; Hayat SMG
J Cell Biochem; 2019 Jun; 120(6):8891-8898. PubMed ID: 30556165
[TBL] [Abstract][Full Text] [Related]
45. Familial combined hyperlipidemia and insulin resistance : distant relatives linked by intra-abdominal fat?
Eckel RH
Arterioscler Thromb Vasc Biol; 2001 Apr; 21(4):469-70. PubMed ID: 11304458
[No Abstract] [Full Text] [Related]
46. Genetics of apolipoprotein B and apolipoprotein AI and premature coronary artery disease.
Zambon A; Brown BG; Deeb SS; Brunzell JD
J Intern Med; 2006 May; 259(5):473-80. PubMed ID: 16629853
[TBL] [Abstract][Full Text] [Related]
47. [Combined familial hyperlipidemia. Study of a family].
Ahumada-Ayala M; Lozano-Castañeda O; Rull JA; Valles VE; Wong B
Rev Invest Clin; 1984; 36(2):141-5. PubMed ID: 6484332
[No Abstract] [Full Text] [Related]
48. Effect of combination nicotinic acid and gemfibrozil treatment on intermediate density lipoprotein, and subclasses of low density lipoprotein and high density lipoprotein in patients with combined hyperlipidemia.
Superko HR; Garrett BC; King SB; Momary KM; Chronos NA; Wood PD
Am J Cardiol; 2009 Feb; 103(3):387-92. PubMed ID: 19166694
[TBL] [Abstract][Full Text] [Related]
49. Polygenic architecture and cardiovascular risk of familial combined hyperlipidemia.
Trinder M; Vikulova D; Pimstone S; Mancini GBJ; Brunham LR
Atherosclerosis; 2022 Jan; 340():35-43. PubMed ID: 34906840
[TBL] [Abstract][Full Text] [Related]
50. A proposal to redefine familial combined hyperlipidaemia -- third workshop on FCHL held in Barcelona from 3 to 5 May 2001, during the scientific sessions of the European Society for Clinical Investigation.
Sniderman AD; Castro Cabezas M; Ribalta J; Carmena R; de Bruin TW; de Graaf J; Erkelens DW; Humphries SE; Masana L; Real JT; Talmud PJ; Taskinen MR
Eur J Clin Invest; 2002 Feb; 32(2):71-3. PubMed ID: 11895451
[No Abstract] [Full Text] [Related]
51. Metabolic syndrome prevalence and characteristics in Greek adults with familial combined hyperlipidemia.
Skoumas J; Papadimitriou L; Pitsavos C; Masoura C; Giotsas N; Chrysohoou C; Toutouza M; Panagiotakos D; Stefanadis C
Metabolism; 2007 Jan; 56(1):135-41. PubMed ID: 17161236
[TBL] [Abstract][Full Text] [Related]
52. Frequent detection of familial hypercholesterolemia mutations in familial combined hyperlipidemia.
Jarvik GP; Brunzell JD; Motulsky AG
J Am Coll Cardiol; 2008 Nov; 52(19):1554-6. PubMed ID: 19007591
[No Abstract] [Full Text] [Related]
53. Hyperlipidemia, dyslipoproteinemia and apolipoproteinopathia--classification and risk of atherosclerosis. Part 2: Hypercholesterolemia.
Choluj B; Votruba T
Acta Univ Carol Med (Praha); 1991; 37(3-4):106-15. PubMed ID: 1845465
[TBL] [Abstract][Full Text] [Related]
54. Unraveling the complex genetics of familial combined hyperlipidemia.
Suviolahti E; Lilja HE; Pajukanta P
Ann Med; 2006; 38(5):337-51. PubMed ID: 16938803
[TBL] [Abstract][Full Text] [Related]
55. [Evaluation of selected risk factors of atherosclerosis in children with type 1 diabetes mellitus and hypercholesterolemia].
Muchacka-Bianga M; Deja G; Jarosz-Chobot P; Małecka-Tendera E; Kalina M; Grychtoł M
Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2006; 12(1):25-30. PubMed ID: 16704858
[TBL] [Abstract][Full Text] [Related]
56. [Diagnosis and treatment of primary hyperlipidemias].
Davignon J
Arq Bras Cardiol; 1982 Jan; 38(1):59-68. PubMed ID: 6756360
[No Abstract] [Full Text] [Related]
57. The dyslipidemia of diabetes mellitus: giving triglycerides and high-density lipoprotein cholesterol a higher priority?
Kendall DM
Endocrinol Metab Clin North Am; 2005 Mar; 34(1):27-48. PubMed ID: 15752920
[TBL] [Abstract][Full Text] [Related]
58. Vascular remodeling and prothrombotic markers in subjects affected by familial combined hyperlipidemia and/or metabolic syndrome in primary prevention for cardiovascular disease.
Cicero AF; Derosa G; Manca M; Bove M; Borghi C; Gaddi AV
Endothelium; 2007; 14(4-5):193-8. PubMed ID: 17922335
[TBL] [Abstract][Full Text] [Related]
59. The association between fibrate use, change in high-density lipoprotein cholesterol, and the risk of cardiovascular disease: a retrospective chart review involving up to 8 years of follow-up.
Nichols GA; Koro CE; Chan W; Bowlin SJ; Sprecher DL
Clin Ther; 2006 Feb; 28(2):243-50. PubMed ID: 16678645
[TBL] [Abstract][Full Text] [Related]
60. [Treatment of dyslipidemia in clinical practice].
Paragh G; Harangi M
Orv Hetil; 2006 Mar; 147(9):389-94. PubMed ID: 16619956
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
